FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is application of biologically active substance for production of medication for treatment of syndrome of resistance to insulin, diabetes, including type I diabetes and type II diabetes, syndrome of ovary polycystosis, treatment or reduction of probability of atheroslerosis development, arterioslerosis, obesity, hypertension, hyperlipidemia, fatty infiltration of liver, nephropathy, neuropathy or retinopathy, feet ulceration or cataracts associated with diabetes, where medication represents compound of formula , as well as corresponding treatment method, pharmaceutical composition and biologically active substance of the same purpose.
EFFECT: increase of compound activity: 75% reduction of glucose level with loading in contrast to 10% reduction for analogues known before, as well as reduction of level of triglycerides in blood serum.
17 cl, 1 dwg, 2 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS FOR TREATMENT OF METABOLIC DISEASES | 2002 |
|
RU2341513C2 |
COMPOUNDS FOR TREATING METABOLIC DISEASES | 2008 |
|
RU2502723C2 |
COMPOUNDS FOR METABOLIC DISORDER TREATMENT | 2004 |
|
RU2349584C2 |
TETRAZOLE COMPOUNDS FOR REDUCING CONCENTRATION OF URIC ACID | 2009 |
|
RU2522458C2 |
COMPOUND FOR TREATING METABOLIC DISORDERS | 2008 |
|
RU2521284C2 |
COMPOUNDS FOR METABOLIC DISORDER TREATMENT | 2004 |
|
RU2358722C2 |
COMPOUNDS AND METHODS FOR URIC ACID REDUCTION | 2009 |
|
RU2501554C2 |
COMPOUNDS AND METHODS FOR URIC ACID REDUCTION | 2009 |
|
RU2501555C2 |
AMINOTETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR TREATING OR PREVENTING DIABETES | 2010 |
|
RU2550508C2 |
FLUOROPHENYL-BETA-HYDROXYETHYLAMINES AND THEIR USE FOR THE TREATMENT OF HYPERGLYCEMIA | 2018 |
|
RU2801096C2 |
Authors
Dates
2011-06-10—Published
2006-11-09—Filed